Discontinued — last reported Q4 '25
Royalty Pharma Net change in loans and leases decreased by 38.3% to $452.37M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 42697.2%, from $1.06M to $452.37M. Over 4 years (FY 2021 to FY 2025), Net change in loans and leases shows a downward trend with a -6.2% CAGR.
A large negative value indicates aggressive loan growth, while a positive value suggests the loan book is shrinking or repayments are outpacing new originations.
This metric reflects the net cash impact of loan originations versus principal repayments received from borrowers. For a...
Highly comparable across commercial and consumer banks.
net_change_in_loans| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $180.67M | $1.34B | $171.73M | $85.00K | $175.01M | $1.32B | $250.24M | $601.71M | $60.45M | $451.13M | $1.00B | $86.08M | $728.63M | $1.19B | $496.42M | $1.06M | $1.11M | $961.87M | $733.69M | $452.37M |
| QoQ Change | — | +639.5% | -87.1% | -100.0% | >999% | +652.1% | -81.0% | +140.5% | -90.0% | +646.3% | +122.2% | -91.4% | +746.4% | +63.9% | -58.4% | -99.8% | +5.4% | >999% | -23.7% | -38.3% |
| YoY Change | — | — | — | — | -3.1% | -1.5% | +45.7% | >999% | -65.5% | -65.7% | +300.5% | -85.7% | >999% | +164.8% | -50.5% | -98.8% | -99.8% | -19.5% | +47.8% | >999% |